Saturday 17 October 2026
Export MBAI’s income statement to Excel — free account
MBody AI Ltd.
MBAI Healthcare Diagnostics & Research
Operating cash flow growth for three consecutive years.
2.75
0.35
−11.29%
Follow MBAI
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 1,629.60 | 1,344.00 | 226.80 | 179.20 | 34.02 | 84.42 | 13.16 | 8.54 | 3.92 | 4.15 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 6,249.60 | 4,435.20 | 2,769.20 | 588.00 | 331.80 | 628.60 | 98.00 | 41.30 | 24.15 | 21.91 | |||||
| People | |||||||||||||||
| People | Employees | 55 | 48 | 56 | 64 | 65 | 81 | 85 | — | — | — | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (9) | (10) | (11) | (14) | (14) | (17) | (19) | (18) | (25) | 4 | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (9) | (10) | (11) | (14) | (14) | (17) | (19) | (18) | (25) | 4 | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (1,024.90) | (940.52) | (365.29) | (242.13) | (63.85) | (29.39) | (23.58) | (20.99) | (30.09) | 4.62 | |||||
| Cash flow | (880.33) | (879.81) | (348.76) | (224.92) | (60.46) | (27.36) | (23.08) | (20.28) | (9.58) | (0.05) | |||||
| Capex | (18.44) | (22.21) | (3.24) | (2.92) | (1.75) | (1.69) | (0.60) | (0.10) | 0.00 | 0.00 | |||||
| Free cash flow | (898.78) | (902.02) | (352.00) | (227.85) | (62.20) | (29.05) | (23.68) | (20.38) | (9.58) | (0.05) | |||||
| Book value | 1,156.33 | 567.79 | 449.31 | 109.18 | 75.51 | 85.27 | 50.97 | 28.34 | (1.73) | 3.86 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (8) | (9) | (10) | (13) | (13) | (16) | (19) | (17) | (8) | 0 | ||||
| Capex | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | — | — | |||||
| Free cash flow | (8) | (9) | (10) | (13) | (13) | (17) | (19) | (17) | (8) | 0 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 11 | 6 | 13 | 6 | 15 | 49 | 39 | 24 | (2) | (4) | ||||
| Total debt | — | — | — | 0 | 0 | 1 | 1 | — | — | — | |||||
| Net debt | (12) | (7) | (15) | (8) | (18) | (52) | (42) | (25) | 0 | 0 | |||||
| Shareholders’ equity | 10 | 6 | 13 | 6 | 16 | 51 | 41 | 24 | (1) | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (63.97) | (96.74) | (90.73) | (111.29) | (95.27) | (45.69) | (37.80) | (49.87) | (198.07) | 105.30 | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (46.09) | |||||
| ROE | (76.56) | (119.80) | (111.85) | (143.65) | (122.47) | (51.30) | (41.54) | (54.06) | (226.19) | 416.71 | |||||
Negative figures in brackets.
Charts ten years each
MBody AI Ltd. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| XGN Exagen Inc. | $207.4M | — (loss-making) | — (loss-making) | +15.92% (above 0%: growing) | n/m | +211.34% (above 0%: growing) | 61.27% | (8.64%) | Compare |
| BNR Burning Rock Biotech Limited Sponsored ADR | $137.1M | — (loss-making) | 11.1× | −4.22% (below 0%: shrinking) | n/m | +46.01% (above 0%: growing) | 72.58% | (13.36%) | Compare |
| MDXHF MedX Health Corp. | $103.2M | — (loss-making) | — (loss-making) | +33.59% (above 0%: growing) | n/m | +41.60% (above 0%: growing) | 37.19% | (1,027.95%) | Compare |
| IMDX Insight Molecular Diagnostics Inc. | $100.1M | — (loss-making) | — (loss-making) | −53.86% (below 0%: shrinking) | n/m | −54.02% (below 0%: shrinking) | 65.69% | (4,770.71%) | Compare |
| QUCY Quantum Cyber N.V | $95.1M | — (loss-making) | — (loss-making) | +11.12% (above 0%: growing) | n/m | +26.73% (above 0%: growing) | 62.71% | 0.00% | Compare |
| MDXH MDxHealth SA | $57.6M | — (loss-making) | — (loss-making) | +12.01% (above 0%: growing) | n/m | −200.20% (below 0%: shrinking) | 65.75% | (18.74%) | Compare |
| MBAI MBody AI Ltd. | $47.4M | — (loss-making) | — | — | n/m | +122.08% (above 0%: growing) | 0.00% | 0.00% | |
| PRPO Precipio, Inc. | $40.4M | — (loss-making) | 15.4× | +24.18% (above 0%: growing) | n/m | +79.59% (above 0%: growing) | 44.67% | (8.53%) | Compare |
| PMD Psychemedics Corporation | $15.7M | — (loss-making) | — (loss-making) | −11.46% (below 0%: shrinking) | n/m | +57.45% (above 0%: growing) | 31.37% | 3.80% | Compare |
| Median of peers | $97.6M | — | — | +11.57% | — | +43.81% | 61.99% | (11.00%) |
MBody AI Ltd. (MBAI) key facts
- MBody AI Ltd. (MBAI) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MBAI traded at $2.75, a market capitalization of $47.4 million.
- Return on equity was 416.7% and debt-to-equity 0.00.